Boston's resTORbio Sets Terms for $85M IPO Post author:Sam Post published:January 16, 2018 Post category:BioPharma resTORbio is developing novel therapies to improve immune function in the elderly. Source: BioSpace You Might Also Like 3 Broker Favorite Biopharmas Your Portfolio Must Have January 17, 2018 Kala Pharma Sinks on Mixed Data From Two Phase III Dry Eye Disease Studies January 4, 2018 Caribou Biosciences Appoints Ph.D. As Chief Scientific Officer July 5, 2017
